We have previously shown that a molecule consisting of a useful for therapeutic purposes. A second nuclease, fusion of a Ca 2+ -dependent nuclease (from Staphylococcus Escherichia coli RNase HI was found to be nontoxic and aureus) to a retroviral coat protein specifies a potent antihighly effective against a murine leukemia virus when it viral specific for that retrovirus. Genes specifying such was fused to the leukemia virus coat protein. The fusion fusion proteins can be delivered to virus-susceptible cells, protein was enzymatically active and stably expressed, providing an antiviral gene therapy aimed at limiting virus without apparent toxicity to host cells. Reduction in infecspread. We report here the results of experiments to vary tious virus output was as high as 97-99%. These studies the nuclease moiety of such fusion proteins. We found that provide a model system for the development of gene theraone nuclease, Serratia marcescens nuclease, was peutic agents aimed at combating retroviral infections in extremely toxic to host cells and hence not likely to be vivo.
Introduction
gene is very different from that of murine Mo(4070A) is Retroviruses assemble their virion cores from coat proused as the delivery vector to introduce the antiviral gagteins specified by their gag genes. We have exploited the SN fusion gene into cells. In the gene therapy model, we rules of this assembly process to devise a novel antiviral first infected cells chronically with Mo(4070A), and then strategy in which the gag genes (or other viral structural treated the culture with the RCAS-gag-SN vector, and genes) are fused to nuclease genes; the fusion proteins observed a 20-to 60-fold reduction in infectious viral titencoded by these antiviral genes are destructive to the ers as a result of the treatment. The treated cells viral genomic RNA. This strategy, referred to as capsidexpressed large amounts of the Gag-SN protein, which targeted viral inactivation (CTVI) has been reduced to are encapsidated into nascent virus particles, in which practice against the yeast retroelement Ty1 1 and the Gag-SN is enzymatically active and hence degrades the murine leukemia virus Mo(4070A), 2, 3 and we have begun Mo(4070A) viral RNA. 3 efforts to target immunodeficiency viruses. 4, 5 Ultimately, The SN antiviral moiety was chosen based on some of we envision delivering CTVI constructs therapeutically, its basic biochemical properties. SN is small, lacks disultargeting either the appropriate virus-susceptible cell fide bonds, and is active against single-and doubletype(s) or the hematopoietic stem cells that sustain such stranded nucleic acids, without extensive sequence specipopulations in infected individuals. 6 If appropriate ficity. 9 An especially interesting property from the perhuman immunodeficiency virus (HIV)-specific genetic spective of gene therapy applications is its absolute antivirals can be delivered efficiently to the appropriate dependence on relatively high concentrations of Ca 2+ . cells, it should be possible to have a significant impact Because intracellular concentrations of calcium ion are on viral load in infected individuals, and recent data tightly regulated at submicromolar levels, this enzyme regarding viral load suggest that it is a most important shows no apparent activity or toxicity when expressed in prognosticator of disease progression in HIV-positive yeast, chicken or mammalian cells. 1,2 Extracellular fluids individuals. 7, 8 typically contain calcium concentrations of several milliThus far, the system in which we have the best data molar, 10 and SN works best at concentrations of about 1 on antiviral effects is with the amphotropic Mo(4070A) millimolar. A down side to the use of bacterial nucleases system, in which we have modeled both antiviral is that they might give rise to an immune response, and prophylaxis 2 and therapy. 3 All of our work to date has might pose significant regulatory hurdles for been with a fusion gene encoding the Mo(4070A) Gag implementing a gene therapy trial. Regrettably, a mamfused to Staphylococcal nuclease (the fusion protein promalian analog of SN (that is, a similarly Ca
2+
-dependent duced is referred to as Gag-SN). In this system, a nonnuclease) has not been described. Therefore, we are exploring other classes of nucleases that are potentially nontoxic and might also have mammalian homologs, in order to explore alternative versions of this antiviral to investigate other classes of nucleases for eventual pracfusion proteins can be used both prophylactically (by infecting first with the RCAS derivative and then chaltical application of CTVI in a gene therapy setting. In this study, we have examined two additional nucleases for lenging with Mo(4070A)) and therapeutically by persistently infecting the culture with Mo(4070A) and then tretheir possible utility in eventual gene therapy applications. These are: (1) the Serratia marcescens nuclease ating the culture with the RCAS derivative. We constructed a set of RCAS proviruses that express (SMN), which is representative of a class of nucleases that is reported to be absolutely dependent on disulfide bond fusion proteins consisting of Mo(4070A) Gag (nucleocapsid) protein fused to SMN and RHI in a manner formation; 11 and (2) RNase HI (RHI) from Escherichia coli, a ribonuclease predicted to attack retroviral replication similar to that previously used to generate the Gag-SN fusion 2 ( Figure 1) . First, the nuclease coding regions were intermediates. 12 Both of these enzymes have mammalian homologs or analogs.
amplified by PCR and sequenced. Then, they were joined to the BamHI site near the 3′-end of the Mo(4070A) gag The S. marcescens SMN enzyme, like SN, attacks both RNA and DNA relatively nonspecifically, but unlike SN, gene to create fusion cassettes. Finally, the fusion cassettes were inserted into the RCAS-BP vector. These vecis active with physiological concentrations of Mg 2+ and does not require calcium ions.
13 Unlike many exotoxic tors can then be transfected into chick embryo fibroblasts (CEF), in which they efficiently replicate until every cell proteins produced by bacteria, there is apparently no 'immunity protein' produced to inactivate SMN. Genetic in the population is infected (at about day 15 after transfection) and expresses the encoded fusion protein. studies indicate that SMN can be tolerated by the cell that produces it because the enzyme is exported via a signal Serratia marcescens nuclease construct is highly sequence and furthermore, the two disulfide bonds in the cytotoxic enzyme are required for activity. 11 Disulfide bonds are We found that when the RCAS gag-SMN virus was transrare in cytoplasmic proteins, but common in secreted profected into cells, the CEF culture reproducibly and drateins. The reducing environment of the cytoplasm, which matically died out, with Ͼ90% cell killing by day 14 after normally contains a 500:1 ratio of reduced to oxidized transfection, a time at which complete infection of the glutathione, is not conducive to the formation of disul-CEF culture is achieved. This lethality was observed fide bonds.
whether or not the cells were previously infected with The E. coli RNase HI enzyme is a representative of an Mo(4070A). We examined this further by investigating ubiquitous cellular enzyme whose cellular role is not the time course of loss of viability ( Figure 2 ). The lethality unambiguously established, but probably plays roles in required expression of the Gag-SMN protein, because DNA replication and repair.
14 RNase H specifically recogcells transfected with a nonexpressing construct grew nizes RNA-DNA hybrid (hence H) duplexes and specifinormally. The observed lethality presumably results from cally degrades the RNA strand. Retroviruses encode an residual intracellular nuclease activity of SMN. SMN is RNase H which is essential for their replication; the not a good candidate for the CTVI approach and this activity is required for strand transfer during minus emphasizes the need for individual testing of nuclease strand DNA synthesis, for generation of the plus strand candidates. primer, and for degradation of the RNA strand to allow synthesis of the plus DNA strand. 15 The specific activity RNase HI is expressed and incorporated into virions of the cellular enzyme (RHI) is approximately 2500-fold
In contrast, the gag-RHI construct, like the gag-SN conhigher than that of the viral enzyme, suggesting that if it struct, showed no signs of overt toxicity to the CEF culcould be targeted to retroviral replication complexes, it ture at any time ( Figure 2 ). We collected culture supermight abrogate retroviral replication processes. We natants from the infected cells and pelleted them to look recognized that RNase HI might be a useful nuclease for evidence of expression and encapsidation of the Gagmoiety for CTVI and provided evidence that it inhibited RHI protein and its proteolytically processed derivatives. murine leukemia virus RT in vitro and had a potent antiThe Gag-RHI protein could be readily detected in the Ty1 effect in vivo. 12 Thus, RHI represented an excellent viral pellet fractions by immunoblotting with antibodies candidate antiviral moiety to test for therapeutic effects raised against E. coli RNase HI ( Figure 3a ) as well as antiin the Mo(4070A) murine leukemia virus system, as we bodies against Mo(4070A) NC protein ( Figure 4 ). Both of have done here. these antibodies react with an approximately 85 kDa low abundance species that corresponds to full-length Gag-RHI protein that has not been processed by the
Results
Mo(4070A) protease. In addition, there is a very abundant species recognized by both antibodies at about 27 New Gag-nuclease fusion constructs targeted against kDa that corresponds to the NC-RHI processed fusion Mo(4070A) virus protein. These results are similar to those previously To obtain uniform delivery of the antiviral transgenes, obtained with Gag-SN, and provide strong evidence that and high-level expression of the putative antiviral prothe Gag-RHI protein is not only being expressed, but is teins, we used the RCAS vector system developed by being efficiently encapsidated into Mo(4070A) virions, Hughes and his collaborators. 2, [16] [17] [18] [19] [20] [21] In this system, inserts where it is acted upon by the Mo(4070A) protease and of up to 2 kb can be delivered in a straightforward way released as an NC-RHI fusion protein. to cells sensitive to the avian-specific Rous sarcoma virus or its amphotropic derivatives, which can infect mamGag-RHI fusion protein is enzymatically active We investigated whether the Gag-RHI fusion protein was malian cells. 22 We have previously shown that RCAS-BP can provide a potent antiviral effect against the unrelated active by an in-gel activity assay. This assay is especially useful because it not only provides evidence for activity murine leukemia virus Mo(4070A) when it expresses a Gag-SN fusion protein in chicken cells.
2,3 These antiviral but also indicates which of the species observed by immunoblotting are active. The activity gel (Figure 3b) ing out quantitative immunoblots on viral pellet fractions from parallel cultures using anti-NC ( Figure 4 , Table 1 ) contains viral pellet samples from the gag-RHI transfection as well as from mock-transfected cells. The latter and anti-CA (not shown) antibodies. The anti-NC immunoblots confirmed the results of the anti-RHI antibodies; control shows that we are not detecting the viral RNase H activity which has different biochemical optima and the species assumed to be NC-RHI indeed reacted strongly with the anti-NC antibody (and not with the hence is not detectably active under the conditions used here. In addition, we include a standard curve of purified anti-CA antibody), and as expected, the 85 kDa species reacted with both anti-NC and anti-CA. The levels of NC-E. coli RNase HI which allows an assessment of the specific activity of the fusion proteins. We conclude from RHI and NC-SN can be directly compared and were less than two-fold different, thus the NC-RHI protein is comparative analysis of the immunoblot and the activity gel that the specific activities of the fusion proteins are expressed and encapsidated most efficiently. The total levels of bulk virions produced in both the gag-SN and very similar (within a factor of 5) to native RNase HI from E. coli. Furthermore, we note that three additional gag-RHI transfected cultures were three-to six-fold higher than those in the mock-transfected culture (Table active species are visible. These presumably represent additional processed forms of the fusion protein.
1). Thus the specific infectivity of these virions is considerably lower than is apparent from inspection of the raw infectivity data presented in Figure 5 , and the Expression levels of Gag-SN, Gag-RHI and viral proteins reduction in specific activities of Gag-SN and Gag-RHI are similar to each other. We examined the relative expression levels of Gag-SN and Gag-RHI. In addition, the expression of Gag-SN was previously shown not to interfere with production of Antiviral effect of Gag-RHI fusion protein The cultures that had been treated by transfection of gagviral proteins or viral assembly. We investigated whether the Gag-RHI fusion protein behaved similarly by carry-SN and gag-RHI proviruses (or mock-treated) were
The Gag-RHI protein is efficiently expressed without apparent toxicity to host cells. The protein is efficiently encapsidated into virions, where it undergoes processing by the Mo(4070A) protease. We do not know whether this proteolytic cleavage is required for the antiviral effect, but it seems likely that untethering the enzyme from the inner capsid surface would allow it better access to the replicating RNA-DNA hybrids that it targets. The NC-RHI fusion protein as well as its precursor (and a very small amount of native RHI-sized material visible in the activity gel) all have enzymatic activity, as assayed both in the gel assay (Figure 3b ) and in a quantitative in vitro RNase HI assay carried out on permeabilized virion preparations (data not shown). The gag-RHI fusion gene is as effective in this tissue culture gene therapy model system as is the previously developed gag-SN fusion gene. We presume that the RNase HI results in an antiviral effect via premature degradation of RNA-DNA hybrids, as expected from in vitro studies 12 or interference with specific steps in the complex reverse transcription pathway. Also, this previous study on Ty1 showed that the active site of RHI was necessary to obtain an 'antiviral' effect. 12 Previous studies of our Mo(4070A) system have shown that foreign proteins without nuclease
Figure 2 Gag-SMN expression is toxic to CEF cells. CEF were transfected with RCAS vector (square), pCAN255 (expressing Gag-RHI, activity fused to the C-terminus of Gag result only in triangle), pGS137 (expressing Gag-SMN, diamond) or pGS145 (circle), modest antiviral effects, much less dramatic than those which is identical to pGS137 except it is cloned in the RCAN vector in
observed here. 3 The action of the RHI on Mo(4070A) Figure   could occur either in the infected cell or prior to that, as
which the insert is not expressed, because the splice acceptor (SA in

1) is absent. Transfected cells were passaged and split 1:3 every 2-4 days .
there is now considerable evidence that reverse transcrip-
Cells were trypsinized, resuspended in a final volume of 10 ml and the
tion can occur, at least in part, before infection.
24-26 Hownumber of viable (Trypan blue-negative) cells per ml medium was determined (Cells/ml). The mean cell numbers were determined from two inde-
ever, further studies will be needed to investigate the pendent transfection series and monitored every 2-4 days for 12 days after
detailed mechanism by which these fusion proteins inter-
transfection. Error bars indicate standard deviations.
fere with viral multiplication in vivo. Finally, unlike SN, RNase H is widely conserved assayed for infectious virus production every 4 days, among prokaryotes and eukaryotes and thus the more using the sensitive S + L − focus formation assay. 23 As can appropriate human RNase H cDNA useful for human be seen in Figure 5 , both the Gag-SN and Gag-RHI progene therapy can be obtained and built into antiviral conteins have similar antiviral effects on infectivity, that is, structs. Such efforts are currently underway. about a 90% decrease in raw titer, and about a 97-99% reduction when the effect of increased number of bulk
Materials and methods
particles in the transfected samples (see previous section and Table 1 ) is accounted for. As is the case with GagPlasmid constructs SN, Gag-RHI maintained its antiviral effect throughout
The SMN gene fragment was kindly provided by Dr the lifetime of the culture (about 15 days after the drop Michael Benedik (University of Houston, TX, USA). We in titer was noted). Thus RNase H based fusion proteins amplified the SMN coding region as a BamHI-SalI restricshow significant promise as antivirals.
tion fragment using PCR and subcloned this fragment (exactly as previously described for SN
) as an in-frame
Discussion gag-SMN fusion gene into the RCAS-BP vector, 21 resulting in the RCAS-gag-SMN plasmid pGS137. The Our studies have shown that not all nucleases are approconstruction and detailed maps of the RCAS replicationpriate to mediate capsid-targeted viral inactivation withcompetent avian retrovirus vector and its derivative pGN out affecting the viability of host cells. The extreme tox-1600 have been described previously. 2, 21 For the RHI conicity of the gag-SMN construct indicates that SMN is struct, we first constructed a gag-RHI gene with appropriprobably killing cells by significant residual nonspecific ate restriction sites at the ends. pRNH1.4 contains the nuclease activity. This is somewhat unexpected because rnhA gene of E. coli and additional nucleic acid sequences disulfide bond formation is required for maximal enzyme AAG CTT CAT and ACT AGT at each end of the gene activity and (presumably) does not occur in the cytofor cloning purposes, namely a HindIII site just 5′ of the plasm or nucleus. This does not mean that all enzymes ATG codon and has a downstream flanking XhoI site. The of the general class of disulfide-bond containing nuclerelevant sequences are: ases are necessarily inappropriate, but that each will have to be tested empirically.
. . . . . . AAG CTT CAT ATG. . .rnhA. . .TAA ACT RNase H on the other hand is a very good candidate AGT. . . . . . . for CTVI, as it has now been shown to be active against two extremely dissimilar retroelements, the Ty1 retrotransposon and the murine leukemia virus Mo(4070A).
pCAN 60, containing the gag-RHI fusion gene, was made
Figure 3 Gag-RHI fusion proteins are expressed and secreted in particulate form. (a) Immunoblot analysis. Incorporation of Gag-RNH fusion proteins into Mo(4070A) virions. Five microliters of Gag-RNH viral pellets from gag-RNH-transfected CEF cells harvested 7 days after transfection were subjected to SDS-polyacrylamide gel electrophoresis and examined by immunoblot analysis with anti-E. coli RNase HI antibodies. Virions (5 l) from the Mo(4070A)-infected CEF cells (MOCK) and purified E. coli RNase HI (0.5-10 ng) were loaded as negative controls and for estimation of E. coli RNase HI expression. Molecular mass markers and estimated masses of the detectable processing products of Gag-RNH fusion proteins are shown. (b) Activity gel analysis. RNase H renaturation gel assay on Mo(4070A) virions containing Gag-RNH fusion proteins. Mo(4070A) virions and purified E. coli RNase HI were electrophoresed in a 15% polyacrylamide gel which contains 32 P-poly(rA)-poly(dT). The picture of the gel for RNase H activity is given as a negative of the autoradiogram; thus RNase H activity appears as a dark band. Molecular mass markers and estimated masses of the detectable processing products of Gag-RNH fusion proteins are shown.
by Klenow filling the HindIII site of pRNH-1.4, prior to purified antibody raised in rabbit against pure E. coli digestion with XhoI. The HindIII-XhoI fragment was then RNase HI as previously described. 12 The reaction was ligated to pGN1542 (a pCla 12-Nco derivative 17 containdeveloped using enhanced chemiluminescence ing Mo(4070A) gag) that had been Klenow filled at the (Amersham Life Sciences, Buckinghamshire, UK). The BamHI site prior to SalI digestion, generating the appromolecular mass of each protein was determined using priate fusion gene (Figure 1) 2-mercaptoethanol) at room temperature. Renaturation of RNase H was achieved by incubating the gel overnight in renaturation buffer. After renaturation the gel was exposed to a radiograph film. The band demonstrating RNase H activity was detected in a dark background as a clear area in which the substrate had been degraded and the soluble radioactivity had leached from the gel. In Figure 3b RNase H activity appears as a dark band because it represents a negative of the autoradiogram.
Cell growth, infection with Mo(4070A), transfection with RCAS derivatives, and Mo(4070A) virus harvesting and titration Growth of CEF cells and infection with Mo(4070A) virus was as described previously. 3 In order to perform transfections CEF cells were grown to a density of 7 × 10 6 to 1 × 10 7 cells per dish, passaged at a 1:3 dilution with trypsin and transfected the next day with 10 g of the recombinant replication-competent avian retrovirus vectors using the calcium-phosphate precipitation method. 29 Spread of the recombinant virus by infection was achieved by passaging the transfected cells every 3-4 days. Collection and resuspension of viral pellets was also as previously described. 2 Titration of infectious Mo(4070A) Independent phosphorimager measurements of total NC protein found in viral pellet preparations were made based on the four dilutions done on each sample. These data agree with our earlier work that shows that NC (and other viral Gag proteins) are overproduced when transfected with gag-based constructs. 3 In these experiments, they have a 2.7-to 6.5-fold higher signal than mock-transfected cells. We assume that this represents an equivalent increase in the number of virions in these cultures. The specific infectivity per virion takes this discrepancy into account and is based on the data from day 7 after transfection ( Figure 5 ). NCDDG-AIDS grant AI35282 to JDB. 16 Hughes SH, Kosic E. Mutagenesis of the region between env and src of the SR-A strain of Rous sarcoma virus for the purpose of constructing helper-independent vectors. Virology 1984; 136:
